Tezacaftor Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Tezacaftor (VX-661) is an oral medication for cystic fibrosis (CF) developed by Vertex Pharmaceuticals. In a combination therapy formulation called Symdeko (tezacaftor plus ivacaftor), it is approved in the U.S. and Canada for CF patients, ages 12 and older, who have two copies of the F508del mutation in the CFTR gene and one minimal function mutation. Symdeko is approved and marketed in the EU as Symkevi.Tezacaftor is not approved as a stand-alone treatment, but as part of a combination therapy.

Verwenden

Tezacaftor is used as a combination therapy with Ivacaftor for the treatment of patients with cystic fibrosis.

Definition

VX-661 is an investigational compound that promotes the maturation of delta F508 mutants of the cystic fibrosis transmembrane conductance regulator (CFTR). Delta F508 CFTR represents a class of CFTR mutation that is characterized by impaired processing of misfolded CFTR proteins and reduced accumulation of the protein at the cell surface. VX-661 is intended to facilitate trafficking of CFTR to the epithelial cell membrane. It may be combined with the CFTR potentiator ivacaftor (Item No. 15145) to stimulate both CFTR accumulation and opening at the apical epithelial surface.

Mechanism of action

The transport of charged ions across cell membranes is normally achieved through the actions of the cystic fibrosis transmembrane regulator (CFTR) protein. This protein acts as a channel and allows for the passage of chloride and sodium. This process affects the movement of water in and out of the tissues. It impacts the production of mucus that lubricates and protects certain organs and body tissues, including the lungs. In the F508del mutation of the CFTR gene, one amino acid is deleted at position 508. Therefore, the CFTR channel function is compromised, resulting in thickened mucus secretions. CFTR correctors such as tezacaftor aim to repair F508del cellular misprocessing. This is done by modulating the position of the CFTR protein on the cell surface to the correct position, allowing for adequate ion channel formation and increased water and salt movement through the cell membrane. The concomitant use of ivacaftor is intended to maintain an open channel, increasing the transport of chloride and reducing thick mucus production.

Tezacaftor Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Tezacaftor Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Shijiazhuang Dingmin Pharmaceutical Sciences Co., Ltd.	+86-0311-67591193 +8613931880626	sales02@dingminpharma.com	China	252	58
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.	+86-18600796368 +86-18600796368	sales@sjar-tech.com	China	456	58
Hangzhou FandaChem Co.,Ltd.	+8615858145714	FandaChem@Gmail.com	China	9087	55
career henan chemical co	+86-0371-86658258 +8613203830695	sales@coreychem.com	China	29880	58
Biochempartner	0086-13720134139	candy@biochempartner.com	CHINA	965	58
BOC Sciences	+1-631-485-4226	inquiry@bocsci.com	United States	19553	58
Chongqing Chemdad Co., Ltd	+86-023-6139-8061 +86-86-13650506873	sales@chemdad.com	China	39894	58
ENBRIDGE PHARMTECH CO., LTD.	+8613812269233	tinayang@enbridgepharm.com	China	322	58
TargetMol Chemicals Inc.	+1-781-999-5354 +1-00000000000	marketing@targetmol.com	United States	32161	58
HANGZHOU CLAP TECHNOLOGY CO.,LTD	86-571-88216897,88216896 13588875226	sales@hzclap.com	CHINA	6312	58

1152311-62-0()Verwandte Suche:

---

• VX-661
• VX-661/VX661
• 1-(2,2-Difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1H-indol-5-yl]-cyclopropanecarboxamide
• Cyclopropanecarboxamide, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1H-indol-5-yl]-
• 1-(2,2-Difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1H-indol-5-yl]-cyclopropanecarboxamide VX661
• (R)-1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-
• CS-956
• VX661/Tezacaftor
• VX 661; VX661;VX-661
• 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide
• VX 661;VX661;VX-661; TEZACAFTOR
• Tezacaftor D4Q: What is Tezacaftor D4 Q: What is the CAS Number of Tezacaftor D4
• VX-661 USP/EP/BP
• (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-Methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxaMide
• tezacaftor(VX661)
• inhibit,Tezacaftor,Inhibitor,VX-661,Cystic fibrosis transmembrane conductance regulator,Autophagy,VX 661,CFTR
• N,3,3-Trimethyl-1,5-dioxaspiro[5.5]undecan-9-amine Hydrochloride (4-Methylaminocyclohexanone 2',2'-Dimethyltrimethylene Ketal Hydrochloride)
• (R)-1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)-N-[1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methyl-2-propyl)-5-indolyl]cyclopropanecarboxamide
• Tezacaftor
• 1152311-62-0
• C26H27F3N2O6
• Inhibitors
• API